Zobrazeno 1 - 10
of 212
pro vyhledávání: '"Parvez Mulani"'
Autor:
Remo Panaccione, Edward V Loftus, David Binion, Kevin McHugh, Shamsul Alam, Naijun Chen, Benoît Guérette, Parvez Mulani, Jingdong Chao
Publikováno v:
Canadian Journal of Gastroenterology, Vol 25, Iss 8, Pp 419-425 (2011)
OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed
Externí odkaz:
https://doaj.org/article/8fc99cce04214177a1efc118cfa7fc8f
Autor:
David G Binion, Edouard Louis, Bas Oldenburg, Parvez Mulani, Arielle G Bensimon, Mei Yang, Jingdong Chao
Publikováno v:
Canadian Journal of Gastroenterology, Vol 25, Iss 9, Pp 492-496 (2011)
OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn’s disease (CD) using a meta-analysis of clinical trials.
Externí odkaz:
https://doaj.org/article/5f147c650ec14007b6fa67fdc98ff5df
Autor:
Murali Sundaram, Martin M. Okun, A. Brett Hauber, Parvez Mulani, F. Reed Johnson, Alexa B. Kimball, Yanjun Bao, Jui-Chen Yang, Teresa L. Kauf
Publikováno v:
Journal of Dermatological Treatment. 26:507-513
Previous studies suggest that efficacy is more important than side-effect risks to psoriasis patients. However, those studies did not consider potentially fatal risks of biologic treatments.To quantify the risks patients are willing to accept for imp
Publikováno v:
Annals of the Rheumatic Diseases
BackgroundThis study assessed the impact of simultaneous achievement of clinical, functional and structural efficacy, herein referred to as comprehensive disease control (CDC), on short-term and long-term work-related outcomes, health-related quality
Autor:
C. Leonardi, Yihua Gu, Martin M. Okun, Ulrich Mrowietz, Jeffrey J. Crowley, Parvez Mulani, Y. Bao, Jeffrey M. Sobell
Publikováno v:
British Journal of Dermatology. 167:658-667
Summary Background The clinical utility of increasing to weekly adalimumab therapy in patients with psoriasis with inadequate response to every other week (eow) dosing is unknown. Objectives (i) To determine the effectiveness of escalating adalimumab
Autor:
Arijit Ganguli, Eric Q. Wu, Yifei Liu, Chun-Po Steve Fan, Arielle G. Bensimon, Parvez Mulani, Mei Yang, Yanjun Bao, Mary Cifaldi
Publikováno v:
Advances in Therapy. 29:620-634
Biologic therapies have demonstrated efficacy and safety in several chronic systemic disorders. The authors indirectly compared response rates and costs per responder associated with biologic treatments for moderate-to-severe Crohn's disease (CD), ps
Autor:
Parvez Mulani, Arielle G. Bensimon, David T. Rubin, Andrew P. Yu, Subrata Ghosh, Jingdong Chao, Paul F. Pollack
Publikováno v:
Inflammatory Bowel Diseases. 18:818-825
Background: Nutritional deficiencies and anemia are common in Crohn's disease (CD). Methods: We evaluated the effect of adalimumab on changes in laboratory values using data from CHARM, in which patients were randomized to adalimumab 40 mg every othe
Autor:
Jingdong Chao, Mei Yang, Parvez Mulani, Eric Q. Wu, Edward V. Loftus, Andrew P. Yu, Annie Guerin
Publikováno v:
American Journal of Gastroenterology. 106:1670-1677
Crohn's disease (CD) is associated with substantial psychosocial burden and increased risks for mental health disorders. This retrospective cohort study compared the risks of developing anxiety disorders and depression and incidences of psychotropic
Autor:
Edouard Louis, Jingdong Chao, David G. Binion, Bas Oldenburg, Mei Yang, Arielle G. Bensimon, Parvez Mulani
Publikováno v:
Canadian Journal of Gastroenterology, Vol 25, Iss 9, Pp 492-496 (2011)
OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn’s disease (CD) using a meta-analysis of clinical trials.METHODS: Study-level results were pooled from all clinical trials of adalimumab for
Autor:
Anne M. Robinson, Paul F. Pollack, Scott E. Plevy, Jean-Frederic Colombel, Jingdong Chao, William J. Sandborn, Parvez Mulani, Stefan Schreiber
Publikováno v:
Inflammatory Bowel Diseases. 17:141-151
Background: Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. Methods: Patients randomized to bl